Used as a key intermediate in the synthesis of rimonabant, a cannabinoid receptor antagonist previously developed for weight management and smoking cessation. It plays a critical role in pharmaceutical research targeting metabolic and neurological disorders. Its structure enables selective binding interactions in receptor-based drug design, making it valuable in developing compounds that modulate appetite and energy balance. Also investigated for potential applications in anti-inflammatory and antipsychotic agents due to its affinity for central nervous system receptors.